Trailblazer-3 - Anderson Clinical Research

This study is closed to enrollment and is no longer accepting new referrals. Please click here to search for other studies currently accepting new study referrals.

The TRAILBLAZER-ALZ 3 is exploring a potential treatment to delay or prevent the onset of Alzheimer’s. This study is looking for men and women ages 65-80 who have normal memory, thinking, mood and behavior patterns, but who may be at risk for developing Alzheimer’s disease in the future.

The TRAILBLAZER-ALZ 3 Study is evaluating an investigational drug to see if it might potentially halt or slow the onset of Alzheimer’s disease symptoms of memory loss by treating the early changes in the brain.

This study involves people who have normal memory, thinking, mood and behavior patterns.

Participants are randomly assigned to one of two groups. They receive either the investigational drug or a placebo (a substance that looks like the investigational drug but contains no active ingredients). Those who receive placebo may have the option to receive the investigational drug at a later time.  

If you qualify, participation can last as long as approximately 4.5 years, but will vary for each participant.